“…26 Recently, cumulative investigates have disclosed that ERS can promote the progression of many diseases, including depression, 27 cardiovascular, 28,29 neurodegenerative diseases, 30 cancer, 31 obesity, and diabetes. [32][33][34][35] These years, numerous investigations have reported that ERS is closely associated with the development of lung diseases such as silicosis, 36 asthma, 37 non-small cell lung cancer, 38 acute lung injury, 39 and IPF. 40,41 It has been demonstrated that during the progress of IPF, ERS is activated and administration of the ERS inhibitors can alleviate fibroblast proliferation and improve lung function, suggesting an important factor of ERS for the pathogenesis of IPF.…”